367 related articles for article (PubMed ID: 32158627)
1. Valproic acid attenuates CCR2-dependent tumor infiltration of monocytic myeloid-derived suppressor cells, limiting tumor progression.
Xie Z; Ikegami T; Ago Y; Okada N; Tachibana M
Oncoimmunology; 2020; 9(1):1734268. PubMed ID: 32158627
[TBL] [Abstract][Full Text] [Related]
2. Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Yan D; Zhang M; Wang L; Adeshakin FO; Liu W; Wan X
Biochem Biophys Res Commun; 2020 Feb; 522(3):604-611. PubMed ID: 31785814
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid attenuates immunosuppressive function of myeloid-derived suppressor cells.
Xie Z; Ago Y; Okada N; Tachibana M
J Pharmacol Sci; 2018 Aug; 137(4):359-365. PubMed ID: 30177294
[TBL] [Abstract][Full Text] [Related]
4. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
[TBL] [Abstract][Full Text] [Related]
5. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells.
Gao W; Zhang X; Yang W; Dou D; Zhang H; Tang Y; Zhong W; Meng J; Bai Y; Liu Y; Yang L; Chen S; Liu H; Yang C; Sun T
J Immunother Cancer; 2019 Aug; 7(1):231. PubMed ID: 31462297
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer.
Liang Y; Wang W; Zhu X; Yu M; Zhou C
Sci Rep; 2022 Jun; 12(1):9619. PubMed ID: 35688951
[TBL] [Abstract][Full Text] [Related]
7. CCR2 and CCR5 co-inhibition modulates immunosuppressive myeloid milieu in glioma and synergizes with anti-PD-1 therapy.
Pant A; Hwa-Lin Bergsneider B; Srivastava S; Kim T; Jain A; Bom S; Shah P; Kannapadi N; Patel K; Choi J; Cho KB; Verma R; Yu-Ju Wu C; Brem H; Tyler B; Pardoll DM; Jackson C; Lim M
Oncoimmunology; 2024; 13(1):2338965. PubMed ID: 38590799
[TBL] [Abstract][Full Text] [Related]
8. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
9. Multimodal Intralesional Therapy for Reshaping the Myeloid Compartment of Tumors Resistant to Anti-PD-L1 Therapy via IRF8 Expression.
Patel A; Oba T; Kajihara R; Yokoi T; Abrams SI; Ito F
J Immunol; 2021 Sep; 207(5):1298-1309. PubMed ID: 34362833
[TBL] [Abstract][Full Text] [Related]
10. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.
Zhang M; Wang L; Liu W; Wang T; De Sanctis F; Zhu L; Zhang G; Cheng J; Cao Q; Zhou J; Tagliabue A; Bronte V; Yan D; Wan X; Yu G
J Immunol Res; 2022; 2022():2253436. PubMed ID: 35785030
[TBL] [Abstract][Full Text] [Related]
11. Shenqi Fuzheng injection modulates tumor fatty acid metabolism to downregulate MDSCs infiltration, enhancing PD-L1 antibody inhibition of intracranial growth in Melanoma.
Ma Y; Qi Y; Zhou Z; Yan Y; Chang J; Zhu X; Han J; Wu H; Tao Y; Fan F
Phytomedicine; 2024 Jan; 122():155171. PubMed ID: 37925891
[TBL] [Abstract][Full Text] [Related]
12. PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice.
Kim W; Chu TH; Nienhüser H; Jiang Z; Del Portillo A; Remotti HE; White RA; Hayakawa Y; Tomita H; Fox JG; Drake CG; Wang TC
Gastroenterology; 2021 Feb; 160(3):781-796. PubMed ID: 33129844
[TBL] [Abstract][Full Text] [Related]
13. Maitake α-glucan promotes differentiation of monocytic myeloid-derived suppressor cells into M1 macrophages.
Masuda Y; Nakayama Y; Shimizu R; Naito K; Miyamoto E; Tanaka A; Konishi M
Life Sci; 2023 Mar; 317():121453. PubMed ID: 36709912
[TBL] [Abstract][Full Text] [Related]
14. 6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice.
Jeanbart L; Kourtis IC; van der Vlies AJ; Swartz MA; Hubbell JA
Cancer Immunol Immunother; 2015 Aug; 64(8):1033-46. PubMed ID: 25982370
[TBL] [Abstract][Full Text] [Related]
15. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
Hou A; Hou K; Huang Q; Lei Y; Chen W
Front Immunol; 2020; 11():783. PubMed ID: 32508809
[TBL] [Abstract][Full Text] [Related]
16. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
17. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.
Hosoi A; Matsushita H; Shimizu K; Fujii S; Ueha S; Abe J; Kurachi M; Maekawa R; Matsushima K; Kakimi K
Int J Cancer; 2014 Apr; 134(8):1810-22. PubMed ID: 24150772
[TBL] [Abstract][Full Text] [Related]
18. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.
Lesokhin AM; Hohl TM; Kitano S; Cortez C; Hirschhorn-Cymerman D; Avogadri F; Rizzuto GA; Lazarus JJ; Pamer EG; Houghton AN; Merghoub T; Wolchok JD
Cancer Res; 2012 Feb; 72(4):876-86. PubMed ID: 22174368
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer.
Takeyama Y; Kato M; Tamada S; Azuma Y; Shimizu Y; Iguchi T; Yamasaki T; Gi M; Wanibuchi H; Nakatani T
Cancer Lett; 2020 Jun; 479():89-99. PubMed ID: 32200039
[TBL] [Abstract][Full Text] [Related]
20. E3 ligase TRIM28 promotes anti-PD-1 resistance in non-small cell lung cancer by enhancing the recruitment of myeloid-derived suppressor cells.
Liang M; Sun Z; Chen X; Wang L; Wang H; Qin L; Zhao W; Geng B
J Exp Clin Cancer Res; 2023 Oct; 42(1):275. PubMed ID: 37865804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
